_id
690db370ccc777a4e85d0ce6
Ticker
AVBP
Name
ArriVent BioPharma, Inc. Common Stock
Exchange
NASDAQ
Address
18 Campus Boulevard, Newtown Square, PA, United States, 19073
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://arrivent.com
Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Last Close
20.26
Volume
110113
Current Price
21.74
Change
0.88
Last Updated
2026-01-20T15:59:18.675Z
Image
data:image/webp;base64,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
Ipo Date
2024-01-26T00:00:00.000Z
Market Cap
861129216
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.976
Sentiment Sources
2
Rating
4.8571
Target Price
40.2333
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
38316000
Operating Income
-38316000
Interest Expense
-
Pretax Income
-34978000
Net Income
-34978000
Eps
-0.8345401016703566
Dividends Per Share
-
Shares Outstanding
41281361
Income Tax Expense
-
EBITDA
-34978000
Operating Margin
-
Total Other Income Expense Net
3338000
Cash
112672000
Short Term Investments
187594000
Receivables
505000
Inventories
-
Total Current Assets
321218000
Property Plant Equipment
49000
Total Assets
326555000
Payables
5933000
Short Term Debt
56000
Long Term Debt
-
Total Liabilities
21558000
Equity
304997000
Bs_currency_symbol
USD
Depreciation
-
Change In Working Capital
-4536000
Cash From Operations
-35798000
Capital Expenditures
0
Cash From Investing
-50760000
Cash From Financing
86465000
Net Change In Cash
-93000
Cf_currency_symbol
USD
PE
-
PB
2.9875262861601914
ROE
-11.468309524355977
ROA
-10.711212506315935
FCF
-35798000
Fcf Percent
-
Piotroski FScore
0
Health Score
42
Deep Value Investing Score
4
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
38316000
Quarters > 0 > income Statement > operating Income
-38316000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-34978000
Quarters > 0 > income Statement > net Income
-34978000
Quarters > 0 > income Statement > eps
-0.8345401016703566
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
41912905
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-34978000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
3338000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
112672000
Quarters > 0 > balance Sheet > short Term Investments
187594000
Quarters > 0 > balance Sheet > receivables
505000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
321218000
Quarters > 0 > balance Sheet > property Plant Equipment
49000
Quarters > 0 > balance Sheet > total Assets
326555000
Quarters > 0 > balance Sheet > payables
5933000
Quarters > 0 > balance Sheet > short Term Debt
56000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
21558000
Quarters > 0 > balance Sheet > equity
304997000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-34978000
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
-4536000
Quarters > 0 > cash Flow > cash From Operations
-35798000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-50760000
Quarters > 0 > cash Flow > cash From Financing
86465000
Quarters > 0 > cash Flow > net Change In Cash
-93000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.8345401016703566
Quarters > 0 > ratios > PB
2.9875262861601914
Quarters > 0 > ratios > ROE
-11.468309524355977
Quarters > 0 > ratios > ROA
-10.711212506315935
Quarters > 0 > ratios > FCF
-35798000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
42
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
33623000
Quarters > 1 > income Statement > operating Income
-33623000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-31399000
Quarters > 1 > income Statement > net Income
-31399000
Quarters > 1 > income Statement > eps
-0.8969576000352396
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
35006114
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-31399000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2224000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
112765000
Quarters > 1 > balance Sheet > short Term Investments
122922000
Quarters > 1 > balance Sheet > receivables
505000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
250149000
Quarters > 1 > balance Sheet > property Plant Equipment
85000
Quarters > 1 > balance Sheet > total Assets
269506000
Quarters > 1 > balance Sheet > payables
4060000
Quarters > 1 > balance Sheet > short Term Debt
98000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
19636000
Quarters > 1 > balance Sheet > equity
249870000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-31399000
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
1964000
Quarters > 1 > cash Flow > cash From Operations
-26124000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
13910000
Quarters > 1 > cash Flow > cash From Financing
75114000
Quarters > 1 > cash Flow > net Change In Cash
62900000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.8969576000352396
Quarters > 1 > ratios > PB
3.0457154454716453
Quarters > 1 > ratios > ROE
-12.566134389882738
Quarters > 1 > ratios > ROA
-11.650575497391525
Quarters > 1 > ratios > FCF
-26124000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
38
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
66772000
Quarters > 2 > income Statement > operating Income
-66772000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-64387000
Quarters > 2 > income Statement > net Income
-64387000
Quarters > 2 > income Statement > eps
-1.8993775627599634
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
33899000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-66772000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2385000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
49865000
Quarters > 2 > balance Sheet > short Term Investments
126212000
Quarters > 2 > balance Sheet > receivables
505000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
185785000
Quarters > 2 > balance Sheet > property Plant Equipment
120000
Quarters > 2 > balance Sheet > total Assets
215495000
Quarters > 2 > balance Sheet > payables
4364000
Quarters > 2 > balance Sheet > short Term Debt
138000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
12953000
Quarters > 2 > balance Sheet > equity
202542000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-64387000
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-5892000
Quarters > 2 > cash Flow > cash From Operations
-68008000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
36821000
Quarters > 2 > cash Flow > cash From Financing
6759000
Quarters > 2 > cash Flow > net Change In Cash
-24428000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-1.8993775627599634
Quarters > 2 > ratios > PB
3.6385750116025313
Quarters > 2 > ratios > ROE
-31.78945601406128
Quarters > 2 > ratios > ROA
-29.878651476832406
Quarters > 2 > ratios > FCF
-68008000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
37
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
23705000
Quarters > 3 > income Statement > operating Income
-23705000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-20633000
Quarters > 3 > income Statement > net Income
-20633000
Quarters > 3 > income Statement > eps
-0.6144100035108292
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
33581810
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-23705000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
3072000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
74293000
Quarters > 3 > balance Sheet > short Term Investments
144570000
Quarters > 3 > balance Sheet > receivables
500000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
226979000
Quarters > 3 > balance Sheet > property Plant Equipment
154000
Quarters > 3 > balance Sheet > total Assets
274942000
Quarters > 3 > balance Sheet > payables
3782000
Quarters > 3 > balance Sheet > short Term Debt
162000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
17288000
Quarters > 3 > balance Sheet > equity
257654000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-20633000
Quarters > 3 > cash Flow > depreciation
-
Quarters > 3 > cash Flow > change In Working Capital
3529000
Quarters > 3 > cash Flow > cash From Operations
-16152000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-192465000
Quarters > 3 > cash Flow > cash From Financing
55000
Quarters > 3 > cash Flow > net Change In Cash
-208562000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.6144100035108292
Quarters > 3 > ratios > PB
2.833523055725896
Quarters > 3 > ratios > ROE
-8.00802626778548
Quarters > 3 > ratios > ROA
-7.504491856464273
Quarters > 3 > ratios > FCF
-16152000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
43
Annuals > 0 > quarter
2024-09-30
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
94308000
Annuals > 0 > income Statement > operating Income
-94308000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-80488000
Annuals > 0 > income Statement > net Income
-80488000
Annuals > 0 > income Statement > eps
-2.557665038160332
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
31469328
Annuals > 0 > income Statement > income Tax Expense
-80488000
Annuals > 0 > income Statement > EBITDA
-80488000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
13820000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
74293000
Annuals > 0 > balance Sheet > short Term Investments
144570000
Annuals > 0 > balance Sheet > receivables
500000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
226979000
Annuals > 0 > balance Sheet > property Plant Equipment
154000
Annuals > 0 > balance Sheet > total Assets
274942000
Annuals > 0 > balance Sheet > payables
3782000
Annuals > 0 > balance Sheet > short Term Debt
162000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
17288000
Annuals > 0 > balance Sheet > equity
257654000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-80488000
Annuals > 0 > cash Flow > depreciation
-
Annuals > 0 > cash Flow > change In Working Capital
7068000
Annuals > 0 > cash Flow > cash From Operations
-70212000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-192465000
Annuals > 0 > cash Flow > cash From Financing
186581000
Annuals > 0 > cash Flow > net Change In Cash
-76096000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-2.557665038160332
Annuals > 0 > ratios > PB
2.6552787487095095
Annuals > 0 > ratios > ROE
-31.238793110139955
Annuals > 0 > ratios > ROA
-29.274537902539443
Annuals > 0 > ratios > FCF
-70212000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-09-30
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
74590000
Annuals > 1 > income Statement > operating Income
-74590000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-69333000
Annuals > 1 > income Statement > net Income
-69333000
Annuals > 1 > income Statement > eps
-2.1695948984901645
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
31956657
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-74590000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
5257000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
150389000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
761000
Annuals > 1 > balance Sheet > inventories
-240000
Annuals > 1 > balance Sheet > total Current Assets
159968000
Annuals > 1 > balance Sheet > property Plant Equipment
291000
Annuals > 1 > balance Sheet > total Assets
163098000
Annuals > 1 > balance Sheet > payables
4532000
Annuals > 1 > balance Sheet > short Term Debt
140000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
11801000
Annuals > 1 > balance Sheet > equity
151297000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-69333000
Annuals > 1 > cash Flow > depreciation
-
Annuals > 1 > cash Flow > change In Working Capital
12596000
Annuals > 1 > cash Flow > cash From Operations
-55842000
Annuals > 1 > cash Flow > capital Expenditures
0
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
42859000
Annuals > 1 > cash Flow > net Change In Cash
-12983000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-2.1695948984901645
Annuals > 1 > ratios > PB
4.591880362333687
Annuals > 1 > ratios > ROE
-45.82575992914598
Annuals > 1 > ratios > ROA
-42.51002464775779
Annuals > 1 > ratios > FCF
-55842000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
29
Annuals > 2 > quarter
2022-09-30
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
36906000
Annuals > 2 > income Statement > operating Income
-36906000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-36906000
Annuals > 2 > income Statement > net Income
-36906000
Annuals > 2 > income Statement > eps
-1.1018772158984884
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
33493750
Annuals > 2 > income Statement > income Tax Expense
-36906000
Annuals > 2 > income Statement > EBITDA
-36906000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
163372000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
500000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
182622000
Annuals > 2 > balance Sheet > property Plant Equipment
139000
Annuals > 2 > balance Sheet > total Assets
182833000
Annuals > 2 > balance Sheet > payables
3094000
Annuals > 2 > balance Sheet > short Term Debt
128000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
8371000
Annuals > 2 > balance Sheet > equity
174462000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-36906000
Annuals > 2 > cash Flow > depreciation
36906000
Annuals > 2 > cash Flow > change In Working Capital
-7149000
Annuals > 2 > cash Flow > cash From Operations
-43631000
Annuals > 2 > cash Flow > capital Expenditures
0
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
169723000
Annuals > 2 > cash Flow > net Change In Cash
126092000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-1.1018772158984884
Annuals > 2 > ratios > PB
4.173711897146656
Annuals > 2 > ratios > ROE
-21.15417684080201
Annuals > 2 > ratios > ROA
-20.18563388447381
Annuals > 2 > ratios > FCF
-43631000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-09-30
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
8696000
Annuals > 3 > income Statement > operating Income
-8696000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-51606000
Annuals > 3 > income Statement > net Income
-51606000
Annuals > 3 > income Statement > eps
-40.435651322233106
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
1276250
Annuals > 3 > income Statement > income Tax Expense
-11594664
Annuals > 3 > income Statement > EBITDA
-51606000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-42910000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
37280000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
250000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
42952000
Annuals > 3 > balance Sheet > property Plant Equipment
0
Annuals > 3 > balance Sheet > total Assets
43039000
Annuals > 3 > balance Sheet > payables
293000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
1818000
Annuals > 3 > balance Sheet > equity
41221000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-51606000
Annuals > 3 > cash Flow > depreciation
11594664
Annuals > 3 > cash Flow > change In Working Capital
-3941000
Annuals > 3 > cash Flow > cash From Operations
-12587000
Annuals > 3 > cash Flow > capital Expenditures
0
Annuals > 3 > cash Flow > cash From Investing
-40000000
Annuals > 3 > cash Flow > cash From Financing
89867000
Annuals > 3 > cash Flow > net Change In Cash
37280000
Annuals > 3 > cash Flow > currency_symbol
-
Annuals > 3 > ratios > PE
-40.435651322233106
Annuals > 3 > ratios > PB
0.6730956308677616
Annuals > 3 > ratios > ROE
-125.19346934814779
Annuals > 3 > ratios > ROA
-119.9052022584168
Annuals > 3 > ratios > FCF
-12587000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
41
Valuation > metrics > PE
-0.8345401016703566
Valuation > metrics > PB
2.9875262861601914
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-11.468309524355977
Profitability > metrics > ROA
-10.88917806598634
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.07068266245241757
Risk > final Score
80
Risk > verdict
Low
Liquidity > metrics > Current Ratio
53.63466354984138
Liquidity > metrics > Quick Ratio
53.63466354984138
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
49.54284554528355
Prev Valuations > 1
43.614249883974686
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
80
Prev Risks > 1
-52
Prev Risks > 2
29
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:26:24.712Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
-0.82
Earnings History > 0 > eps Difference
0.82
Earnings History > 0 > surprise Percent
100
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-10
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.83
Earnings History > 1 > eps Estimate
-0.79
Earnings History > 1 > eps Difference
-0.04
Earnings History > 1 > surprise Percent
-5.0633
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-11
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.9
Earnings History > 2 > eps Estimate
-0.76
Earnings History > 2 > eps Difference
-0.14
Earnings History > 2 > surprise Percent
-18.4211
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-12
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-1.9
Earnings History > 3 > eps Estimate
-0.73
Earnings History > 3 > eps Difference
-1.17
Earnings History > 3 > surprise Percent
-160.274
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-03
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.6
Earnings History > 4 > eps Estimate
-0.46
Earnings History > 4 > eps Difference
-0.14
Earnings History > 4 > surprise Percent
-30.4348
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-15
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.61
Earnings History > 5 > eps Estimate
-0.54
Earnings History > 5 > eps Difference
-0.07
Earnings History > 5 > surprise Percent
-12.963
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-14
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.65
Earnings History > 6 > eps Estimate
-0.51
Earnings History > 6 > eps Difference
-0.14
Earnings History > 6 > surprise Percent
-27.451
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-05-08
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.7
Earnings History > 7 > eps Estimate
-1.2963
Earnings History > 7 > eps Difference
0.5963
Earnings History > 7 > surprise Percent
46.0002
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-03-28
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-0.7
Earnings History > 8 > eps Estimate
-1.1
Earnings History > 8 > eps Difference
0.4
Earnings History > 8 > surprise Percent
36.3636
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AArriVent stock rating reiterated as Overweight by Cantor Fitzgerald - Investing.com Nigeria
1/16/2026
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald Investing.com Nigeria
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$40.2333
Analyst Picks
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of ArriVent BioPharma, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.82
Date
2025-09-30
EPS Actual
-0.83
EPS Estimate
-0.79
EPS Difference
-0.04
Surprise Percent
-5.0633%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.